169 related articles for article (PubMed ID: 29072371)
1. HER2 exon 27 mutations predict worse survival of breast cancer patients, especially in HER2-negative patients.
Si P; Chen T; Fang B; Yao J; Liu G; Chen H; Zhai B; Li W
Cancer Med; 2017 Dec; 6(12):2832-2839. PubMed ID: 29072371
[TBL] [Abstract][Full Text] [Related]
2. Association between HER2 germline mutation A270S and prognosis in patients with primary breast cancer.
Si P; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Cancer Biomark; 2018; 23(2):165-171. PubMed ID: 30175972
[TBL] [Abstract][Full Text] [Related]
3. Impact of triple negative phenotype on breast cancer prognosis.
Kaplan HG; Malmgren JA
Breast J; 2008; 14(5):456-63. PubMed ID: 18657139
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
5. Molecular phenotypes of DCIS predict overall and invasive recurrence.
Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
[TBL] [Abstract][Full Text] [Related]
6. Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype.
Theriault RL; Litton JK; Mittendorf EA; Chen H; Meric-Bernstam F; Chavez-Macgregor M; Morrow PK; Woodward WA; Sahin A; Hortobagyi GN; Gonzalez-Angulo AM
Clin Breast Cancer; 2011 Oct; 11(5):325-31. PubMed ID: 21764391
[TBL] [Abstract][Full Text] [Related]
7. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.
Karachaliou N; Mayo-de las Casas C; Queralt C; de Aguirre I; Melloni B; Cardenal F; Garcia-Gomez R; Massuti B; Sánchez JM; Porta R; Ponce-Aix S; Moran T; Carcereny E; Felip E; Bover I; Insa A; Reguart N; Isla D; Vergnenegre A; de Marinis F; Gervais R; Corre R; Paz-Ares L; Morales-Espinosa D; Viteri S; Drozdowskyj A; Jordana-Ariza N; Ramirez-Serrano JL; Molina-Vila MA; Rosell R;
JAMA Oncol; 2015 May; 1(2):149-57. PubMed ID: 26181014
[TBL] [Abstract][Full Text] [Related]
8. Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.
Ramirez-Ardila DE; Helmijr JC; Look MP; Lurkin I; Ruigrok-Ritstier K; van Laere S; Dirix L; Sweep FC; Span PN; Linn SC; Foekens JA; Sleijfer S; Berns EM; Jansen MP
Breast Cancer Res Treat; 2013 May; 139(1):39-49. PubMed ID: 23592373
[TBL] [Abstract][Full Text] [Related]
9. HER2 somatic mutations are associated with poor survival in HER2-negative breast cancers.
Wang T; Xu Y; Sheng S; Yuan H; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Cancer Sci; 2017 Apr; 108(4):671-677. PubMed ID: 28164408
[TBL] [Abstract][Full Text] [Related]
10. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
Perez EA; Ballman KV; Tenner KS; Thompson EA; Badve SS; Bailey H; Baehner FL
JAMA Oncol; 2016 Jan; 2(1):56-64. PubMed ID: 26469139
[TBL] [Abstract][Full Text] [Related]
11. Low expression of RECQL is associated with poor prognosis in Chinese breast cancer patients.
Xu H; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
BMC Cancer; 2018 Jun; 18(1):662. PubMed ID: 29914420
[TBL] [Abstract][Full Text] [Related]
12. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
[TBL] [Abstract][Full Text] [Related]
13. Negative/low HER2 expression alone or combined with E-cadherin positivity is predictive of better prognosis in patients with breast carcinoma.
Karray-Chouayekh S; Trifa F; Khabir A; Sellami-Boudawara T; Frikha M; Gargouri A; Mokdad-Gargouri R
Histol Histopathol; 2012 Mar; 27(3):377-85. PubMed ID: 22237715
[TBL] [Abstract][Full Text] [Related]
14. Host genotype and tumor phenotype of chemokine decoy receptors integrally affect breast cancer relapse.
Yu KD; Wang X; Yang C; Zeng XH; Shao ZM
Oncotarget; 2015 Sep; 6(28):26519-27. PubMed ID: 26314842
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.
Anglesio MS; Kommoss S; Tolcher MC; Clarke B; Galletta L; Porter H; Damaraju S; Fereday S; Winterhoff BJ; Kalloger SE; Senz J; Yang W; Steed H; Allo G; Ferguson S; Shaw P; Teoman A; Garcia JJ; Schoolmeester JK; Bakkum-Gamez J; Tinker AV; Bowtell DD; Huntsman DG; Gilks CB; McAlpine JN
J Pathol; 2013 Jan; 229(1):111-20. PubMed ID: 22899400
[TBL] [Abstract][Full Text] [Related]
16. Expression of SATB1 and HER2 in breast cancer and the correlations with clinicopathologic characteristics.
Liu X; Zheng Y; Qiao C; Qv F; Wang J; Ding B; Sun Y; Wang Y
Diagn Pathol; 2015 May; 10():50. PubMed ID: 25956130
[TBL] [Abstract][Full Text] [Related]
17. Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older.
Kim MH; Kim GM; Kim JH; Kim JY; Park HS; Park S; Cho YU; Park BW; Kim SI; Sohn J
Breast Cancer Res Treat; 2020 Feb; 179(3):687-697. PubMed ID: 31811505
[TBL] [Abstract][Full Text] [Related]
18. Moderate level of HER2 expression and its prognostic significance in breast cancer with intermediate grade.
Ignatov T; Eggemann H; Burger E; Fettke F; Costa SD; Ignatov A
Breast Cancer Res Treat; 2015 Jun; 151(2):357-64. PubMed ID: 25926338
[TBL] [Abstract][Full Text] [Related]
19. The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer.
Toomey S; Madden SF; Furney SJ; Fan Y; McCormack M; Stapleton C; Cremona M; Cavalleri GL; Milewska M; Elster N; Carr A; Fay J; Kay EW; Kennedy S; Crown J; Gallagher WM; Hennessy BT; Eustace AJ
Oncotarget; 2016 Nov; 7(46):75518-75525. PubMed ID: 27776352
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]